Viscosupplementation Market is predicted to reach US$ 2.89 Billion by 2030

Global sales of viscosupplementation equipment are expected to reach US$ 1.98 billion. According to a detailed industry analysis, the global Viscosupplementation Market is expected to grow at a CAGR of 4.8% to reach a market valuation of US$ 2.89 Billion by 2030.

According to new research from ESOMAR-certified firm Future Market Insights, global viscosupplementation revenues are expected to reach USD 4 billion by the end of 2030.

According to the UN, by 2050, those aged 60 and up will account for more than 20% of the global population. In other words, the UN predicts that by 2050, approximately 130 million people will suffer from osteoarthritis. These figures indicate that the viscosupplementation market will expand during the forecast period.

Full Information Source @ https://www.futuremarketinsights.com/reports/viscosupplementation-market

Key Takeaways of Viscosupplementation Market Study

Three injection viscosuppplementation is expected to contribute for more than 55% of revenue share
Knee osteoarthritis is expected to gain around one-third of market share during the forecast period
North America is the highest revenue generating market due to scientific advancements and high adoption of viscosuppplementation.

New Product Development to be the Torchbearer

The market players are into the innovation mode to strengthen their foothold in the viscosupplementation market. This competitive landscape is all set to create ripples all across the market. Some of the innovations are:

Fidia Pharma USA Inc., in 2019, introduced a HA (Hyaluronic Acid) based intra-articular viscosupplement called “TRILURON” to treat knee osteoarthritis. The treatments cycle involves 3 injections at weekly intervals.
Japan-based Seikagaku Corporation, in Mar 2019, launched an intra-articular single-injection viscosupplement called “HyLink” in Italy for treating knee osteoarthritis.
Recently, Gel-One Hyaluronate was approved as one of the injectable gels to treat osteoarthritis of knee. The pre-market clinical study reported no pseudosepsis (severe acute inflammatory responses).

Key Companies Profiled: